Segment Information

12 Months Ended

Jun. 30, 2016

Segment Reporting [Abstract]

Segment Information

(19) Segment Information

The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

Human Health - includes finished dosage form generic drugs and nutraceutical products.

Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).

Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.

Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.

The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.

	Human Health		Pharmaceutical Ingredients		Performance Chemicals		Unallocated Corporate			Consolidated Totals
2016
Net sales	$	228,035	$	161,011	$	169,478	$	-		$	558,524
Gross profit		77,880		28,752		36,153		-			142,785
Income before income taxes		36,362		11,856		17,799		(12,163	)		53,854
2015
Net sales	$	225,263	$	149,296	$	172,392	$	-		$	546,951
Gross profit		75,749		26,683		33,002		-			135,434
Income before income taxes		35,152		8,697		14,289		(4,273	)		53,865
2014
Net sales	$	160,217	$	176,425	$	173,537	$	-		$	510,179
Gross profit		48,496		36,615		29,592		-			114,703
Income before income taxes		19,710		17,557		13,273		(5,866	)		44,674

Net sales and gross profit by source country for the years ended June 30, 2016, 2015 and 2014 were as follows:

	Net Sales						Gross Profit
	2016		2015		2014		2016		2015		2014
United States	$	400,883	$	407,101	$	355,715	$	117,180	$	111,734	$	82,573
Germany		76,666		69,889		84,024		15,154		14,660		22,614
Netherlands		16,217		14,656		14,869		1,598		1,325		1,581
France		30,177		27,976		29,412		4,043		3,634		4,182
Asia-Pacific		34,581		27,329		26,159		4,810		4,081		3,753
Total	$	558,524	$	546,951	$	510,179	$	142,785	$	135,434	$	114,703

Sales generated from the United States to foreign countries amounted to $23,810, $38,295 and $31,156 for the fiscal years ended June 30, 2016, 2015 and 2014, respectively.

Long-lived assets by geographic region as of June 30, 2016 and June 30, 2015 were as follows:

	Long-lived assets
	2016		2015
United States	$	152,701	$	152,886
Europe		2,504		2,544
Asia-Pacific		1,781		1,893
Total	$	156,986	$	157,323